Document is current
Any future updates will be listed below
-
Authors
Kalyesubula, Robert http://orcid.org/0000-0003-3211-163X
Fabian, June
Nakanga, Wisdom
Newton, Robert
Ssebunnya, Billy
Prynn, Josephine
George, Jaya
Wade, Alisha N.
Seeley, Janet
Nitsch, Dorothea
Hansen, Christian
Nyirenda, Moffat
Smeeth, Liam
Naicker, Saraladevi
Crampin, Amelia C.
Tomlinson, Laurie A.
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Africa Non-Communicable Disease (NCD) Open Lab (8111 uganda; 074 South Africa)
Welcome Trust intermediate Clinical Fellowship (101143/Z/13/Z)
Fogarty International Center (K43TW010698)
- License Information
-
More Information
Article History
Received: 17 May 2019
Accepted: 8 January 2020
First Online: 15 January 2020
Ethics approval and consent to participate
: We have obtained ethical approvals from the Uganda Virus Research Institute, Research Ethics Committee (UVRI-REC) the Uganda National Council for Science and Technology (UNCST), from the Malawi National Health Sciences Research Committee and the University of Witwatersrand Human Research Ethics Committee (Medical).We will obtain written informed consent from participants for the collection and analysis of genetic samples as well as iohexol testing and for the use of their clinical records for research purposes. We will seek approval for all study procedures including material transfer agreements from the respective ethical review boards. In case we diagnose medical conditions through study screening, we will refer the participants to appropriate medical facilities. We will refer participants found to have advanced CKD to appropriate nephrology services as directed by the study physicians in each centre.
: Not applicable
: The authors declare that they have no competing interests.
